A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes

Journal of the American College of Cardiology

Volumn 55, Issue 23, 2010, Pages 2556-2566

  Mehran, Roxana ^a   Pocock, Stuart J ^b   Nikolsky, Eugenia ^a   Clayton, Tim ^b   Dangas, George D ^a   Kirtane, Ajay J ^a   Parise, Helen ^a   Fahy, Martin ^a   Manoukian, Steven V ^c   Feit, Frederick ^d   Ohman, Magnus E ^e   Witzenbichler, Bernard ^f   Guagliumi, Giulio ^g   Lansky, Alexandra J ^a   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HOSPITAL CORPORATION OF AMERICA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g OSPEDALI RIUNITI   (Italy)

Author keywords

bleeding; mortality; myocardial infarction; risk score

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGING; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; FEMALE; HEART CATHETERIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77952738970     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.09.076     Document Type: Article

References (45)

1. Kinnaird T.D., Stabile E., Mintz G.S., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
2. Rao S.V., O'Grady K., Pieper K.S., et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
3. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-882
4. Rao S.V., O'Grady K., Pieper K.S., et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47 (2006) 809-816
5. Feit F., Voeltz M.D., Attubato M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention: an analysis of the REPLACE-2 trial. Am J Cardiol 100 (2007) 1364-1369
6. Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
7. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
8. Lauer M.A., Karweit J.A., Cascade E.F., Lin N.D., and Topol E.J. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol 89 (2002) 924-929
9. Lincoff A.M., Bittl J.A., Harrington R.A., et al., REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
10. Yusuf S., Mehta S.R., Chrolavicius S., et al., Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
11. Stone G.W., White H.D., Ohman E.M., et al., Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial Investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
12. Alexander K.P., Chen A.Y., Roe M.T., et al., CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
13. Sciahbasi A., Pristipino C., Ambrosio G., et al. Arterial access-site-related outcomes of patients undergoing invasive coronary procedures for acute coronary syndromes (from the ComPaRison of Early Invasive and Conservative Treatment in Patients With Non-ST-ElevatiOn Acute Coronary Syndromes [PRESTO-ACS] Vascular Substudy). Am J Cardiol 103 (2009) 796-800
14. Wiviott S.D., Braunwald E., McCabe C.H., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
15. Haas S. Rivaroxaban-an oral, direct Factor Xa inhibitor: lessons from a broad clinical study program. Eur J Haematol 82 (2009) 339-349
16. Stone G.W., Bertrand M.E.M., et al., ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297 (2007) 591-602
17. Stone G.W., Bertrand M., Colombo A., et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148 (2004) 764-775
18. Mehran R., Brodie B., Cox D.A., et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 156 (2008) 44-56
19. Stone G.W., Witzenbichler B., Guagliumi G., et al., HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
20. Altman D.G., and De Stavola B.L. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13 (1994) 301-341
21. Robertson T., Kennard E.D., Mehta S., et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol 80 (1997) 26K-39K
22. Huynh T., Piazza N., DiBattiste P.M., et al. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. Int J Cardiol 100 (2005) 73-78
23. Berger P.B., Best P.J., Topol E.J., et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 149 (2005) 869-875
24. Avezum A., Makdisse M., Spencer F., et al., GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149 (2005) 67-73
25. Montalescot G., Sideris G., Meuleman C., et al., ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
26. Lotrionte M., Biondi-Zoccai G.G., Agostoni P., et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 100 (2007) 1199-1206
27. Collet J.P., Silvain J., Landivier A., et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 118 (2008) 1225-1233
28. Joyner C.D., Peters R.J., Afzal R., et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J 157 (2009) 502-508
29. Gurm H.S., Smith D.E., Collins J.S., et al., Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 51 (2008) 529-535
30. Topol E.J., Moliterno D.J., Herrmann H.C., et al., TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
31. Suleiman M., Gruberg L., Hammerman H., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol 15 (2003) 319-323
32. Valgimigli M., Percoco G., Malagutti P., et al., STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
33. Montalescot G., Steg P.G., Cohen M., White H., Gallo R., Steinhubl S.R., and STEEPLE Investigators. Development and validation of a bleeding risk score model for major bleeding in patients undergoing elective percutaneous coronary intervention: the STEEPLE Trial (abstr). Circulation 114 (2006) II648
34. Nikolsky E., Mehran R., Dangas G., et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 28 (2007) 1936-1945
35. Tang E.W., Wong C.K., and Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 153 (2007) 29-35
36. Subherwal S., Bach R.G., Chen A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 119 (2009) 1873-1882
37. Mehran R., Pocock S.J., Stone G.W., et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30 (2009) 1457-1466
38. Yan A.T., Yan R.T., Huynh T., et al., INTERACT Investigators. Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J 156 (2008) 769-775
39. Nikolsky E., Aymong E.A., Halkin A., et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the CADILLAC trial. J Am Coll Cardiol 44 (2004) 547-553
40. Roy P., Bonello L., Torguson R., et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 102 (2008) 1614-1617
41. Pawloski J.R., and Stamler J.S. Nitric oxide in RBCs. Transfusion 12 (2002) 1603-1609
42. Reynolds J.D., Ahearn G.S., Angelo M., Zhang J., Cobb F., and Stamler J.S. S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A 104 (2007) 17058-17062
43. Doyle B.J., Ting H.H., Bell M.R., et al. Major femoral bleeding complications after percutaneous coronary intervention. Incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. J Am Coll Cardiol Intv 1 (2008) 202-209
44. Fox K.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 110 (2004) 1202-1208
45. Ebrahimi R., Dyke C., Mehran R., et al. Outcomes following preoperative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY trial. J Am Coll Cardiol 53 (2009) 1965-1972